Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent hemodialysis

  1. Fritz Sörgel
  2. Jakob J. Malin
  3. Henning Hagmann
  4. Martina Kinzig
  5. Muhammad Bilal
  6. Dennis A. Eichenauer
  7. Oliver Scherf-Clavel
  8. Alexander Simonis
  9. Lobna El Tabei
  10. Uwe Fuhr
  11. Jan Rybniker
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Remdesivir, a drug with provisional approval for the treatment of COVID-19, is not recommended in patients with an estimated glomerular filtration rate ≤ 30 mL/min. Here we provide a first detailed pharmacokinetic assessment of remdesivir and its major metabolites in a patient with end stage renal disease on hemodialysis.

Related articles

Related articles are currently not available for this article.